Close Menu

cancer of unknown primary

NEW YORK (GenomeWeb News) – A Medicare contractor has issued a final coverage determination confirming coverage for one of Rosetta Genomics' microRNA-based cancer diagnostics, but denying Medicare coverage for two of the firm's other tests, Rosetta announced today.

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has signed a credentialing agreement with Three Rivers Provider Network, which will offer the firm's Cancer Origin Test to members of the preferred provider organization.

Rosetta Genomics released an abstract for this years' annual meeting of the American Society of Clinical Oncology reiterating the concordance and sensitivity of its diagnostic test for cancers of unknown primary origin, and showing that the test frequently influences clinical dec

NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.

In a prospective study published this month, patients with cancer of unknown primary who were tested using BioTheranostics' CancerType ID assay, and who then received chemotherapy specific to their predicted tumor of origin, survived longer on average than expected for standard C

Rosetta Genomics last week published data validating its miRview Mets 2 cancer of unknown primary origin diagnostic.

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that Novitas, a designated Medicare contractor, has informed the firm that it plans to cover its miRview mets2 assay for all Medicare beneficiaries.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has granted the firm approval to begin processing patient samples from the state for its miRview mets^2 test.

Data from the study showed that Rosetta's array-based Mets 2 test has 88 percent concordance with clinical presentation and pathology, exceeding the accuracy of the PCR-based version of the test.

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.